Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

doi:10.1186/s40425-019-0538-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

Journal for immunotherapy of cancer - 12 Mar 2019

Erbe Amy K, Wang Wei, Carmichael Lakeesha, Hoefges Anna, Grzywacz Bartosz, Reville Patrick K, Ranheim Erik A, Hank Jacquelyn A, Kim KyungMann, Seo Songwon, Mendonca Eneida A, Song Yiqiang, Kenkre Vaishalee P, Hong Fangxin, Gascoyne Randy D, Paietta Elisabeth, Horning Sandra J, Miller Jeffrey S, Kahl Brad, Sondel Paul M

Abstract excerpt

BACKGROUND: The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-responding patients were randomized to receive rituximab every 13 weeks ("maintenance") vs. no additional rituximab until progression ("non-maintenance"). Based on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HLA-B Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-C Antigens

Share to Lymphoma, Follicular

Share to Maintenance Chemotherapy

Share to Proportional Hazards Models

Share to Receptors, KIR2DL2

Share to Receptors, KIR3DL1

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 30871628
DOI: 10.1186/s40425-019-0538-8
PMCID: PMC6419437

Genes

KIR2DL2
KIR3DL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.PMID 30871628Read ↗

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.Semantic proximity Read ↗

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.Semantic proximity Read ↗

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.Semantic proximity Read ↗

Comprehensive genetic and functional analysis of FcγRs in rituximab therapy for autoimmunity reveals a key role for FcγRIIIa on NK cellsSemantic proximity Read ↗

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.Semantic proximity Read ↗

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survivalSemantic proximity Read ↗

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.Semantic proximity Read ↗

Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome.Semantic proximity Read ↗

Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma.Semantic proximity Read ↗

Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.Semantic proximity Read ↗

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.Semantic proximity Read ↗

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.